# A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

> **NCT02982486** · PHASE2 · UNKNOWN · sponsor: **Assaf-Harofeh Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Soft Tissue Sarcoma
- Bone Sarcoma
- Chondrosarcoma
- Gastrointestinal Stromal Sarcoma
- Ewing's Tumor Metastatic
- Ewing's Tumor Recurrent
- Osteosarcoma
- Desmoplastic Small Round Cell Tumor

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02982486
- **Lead sponsor:** Assaf-Harofeh Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12
- **Primary completion:** 2020-06
- **Final completion:** 2020-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02982486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02982486, "A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02982486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*